National guideline for the management of pelvic infection and perihepatitis. Clinical Effectiveness Group (Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases).
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002440:Cefoxitin / Q000627:therapeutic use; D002443:Ceftriaxone / Q000627:therapeutic use; D002939:Ciprofloxacin / Q000627:therapeutic use; D002981:Clindamycin / Q000627:therapeutic use; D016358:Contact Tracing; D005260:Female; D005832:Genital Diseases, Male / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D008297:Male; D015242:Ofloxacin / Q000627:therapeutic use; D000292:Pelvic Inflammatory Disease / Q000175:diagnosis / Q000188:drug therapy*; D010538:Peritonitis / Q000175:diagnosis / Q000188:drug therapy*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000175:diagnosis / Q000188:drug therapy; D012749:Sexually Transmitted Diseases / Q000175:diagnosis / Q000188:drug therapy*
D000900:Anti-Bacterial Agents; D002981:Clindamycin; D002939:Ciprofloxacin; D002440:Cefoxitin; D002443:Ceftriaxone; D015242:Ofloxacin